Key result
ECCO2R lacks outcome benefits and carries significant bleeding risk despite achieving ultraprotective ventilation goals.
Why the study?
The clinical benefits and risk–benefit balance of ECCO2R in ARDS, obstructive lung failure, and bridging to lung transplantation remain unclear due to lack of evidence.
Does extracorporeal carbon dioxide removal (ECCO2R) improve outcomes in patients with ARDS or obstructive lung failure?
Does extracorporeal carbon dioxide removal (ECCO2R) improve outcomes in patients with ARDS or obstructive lung failure?
ECCO2R is not currently recommended as standard therapy for ARDS due to lack of outcome benefits and significant bleeding risks, and should be restricted to clinical studies and experienced centers.
Answers are grounded in this paper and cite their sources.
Does not support routine ECCO2R use in ARDS; leaves its role in obstructive lung failure unresolved pending RCTs.
The therapeutic target of extracorporeal carbon dioxide removal (ECCO2R) is the elimination of carbon dioxide (CO2) from the blood across a gas exchange membrane without influencing oxygenation to a clinically relevant extent. In acute respiratory distress syndrome (ARDS), ECCO2R has been used to reduce tidal volume, plateau pressure, and driving pressure (“ultraprotective ventilation”). Despite achieving these goals, no benefits in outcome could be shown. Thus, in ARDS, the use of ECCO2R to achieve ultraprotective ventilation can no longer be recommended. Furthermore, ECCO2R has also been used to avoid intubation or facilitate weaning in obstructive lung failure as well as to avoid mechanical ventilation in patients during bridging to lung transplantation. Although these goals can be achieved in many patients, the effects on outcome still remain unclear due to lack of evidence. Despite involving less blood flow, smaller cannulas, and smaller gas exchange membranes compared with extracorporeal membrane oxygenation, ECCO2R bears a comparable risk of complications, especially bleeding. Trials to define indications and analyze the risk–benefit balance are needed prior to implementation of ECCO2R as a standard therapy. Consequently, until then, ECCO2R should be used in clinical studies and experienced centers only. This article is freely available.
No takes yet. Share an insight, caveat, or question.
Thomas Staudinger (2024) conducted a review in Acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and lung transplantation bridging. Extracorporeal carbon dioxide removal (ECCO2R) was evaluated. Extracorporeal carbon dioxide removal (ECCO2R) achieves ultraprotective ventilation goals but has not demonstrated outcome benefits and carries a significant risk of bleeding complications.
Synapse has enriched 10 related papers. Consider them for comparative context: